Mutations of the BRAF gene in human cancer
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Cancers arise owing to the accumulation of mutations in critical genes that alter normal programmes of cell proliferation, differentiation and death. As the first stage of a systematic genome-wide screen for these genes, we have prioritized for analysis signalling pathways in which at least one gene is mutated in human cancer. The RAS RAF MEK ERK MAP kinase pathway mediates cellular responses to growth signals. RAS is mutated to an oncogenic form in about 15% of human cancer. The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS. Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers. All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%. Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells. Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation. As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The hotspot BRAF V600E mutation at codon 600 of exon 15 increases the activity of BRAF kinase by 130- to 700-fold [26, 93–95].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [95]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAFV600E mutations occur in ∼10% of colorectal cancer (CRC) patients, leading to poor prognosis.”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAFV600E mutations are present in around 10% of advanced CRC patients and lead to constitutive activation of the MAPK pathway, drug resistance and a poor prognosis [1–4].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BRAF mutations occur in roughly 5–15% of CRCs (1–3, 17)”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [17]
In the citing paper
“Among patients with colorectal cancer, there is an approximately 10% incidence of BRAF mutation [36].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [36]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243 · cited 1×
“There has recently been marked success reported of an inhibitor (STI571) of the BCR-ABL kinase in the treatment of chronic myeloid leukaemi”
BackgroundIdentification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015 · cited 1×
“To evaluate whether activating mutations of BRAF signal through MEK and ERK, we treated cells with the MEK1/2 inhibitor U0126 (ref”
MethodMeaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
Kölch, W. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510289 · Cited by 1,441 · cited 1×
“The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RA”
BackgroundRequirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells
Mulcahy, L. S., Smith, M. R., & Stacey, D. W. (1985) · Nature · doi:10.1038/313241a0 · Cited by 878 · cited 1×
“Studies using injection of the RAS-neutralizing Y13-259 monoclonal antibody have previously shown that most normal cells examined and some tumour cells require RAS function for proliferation in cultur”
MethodThe Raf/MEK/ERK pathway: new concepts of activation
Peyssonnaux, C., & Eychène, A. (2001) · Biology of the Cell · doi:10.1016/s0248-4900(01)01125-x · Cited by 735 · cited 1×
“The RAS–RAF–MEK–ERK–MAP kinase pathway mediates cellular responses to growth signal”
BackgroundIncreasing Complexity of the Ras Signaling Pathway
Vojtek, A. B., & Der, C. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.19925 · Cited by 579
Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation
Mason, C. S. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2137 · Cited by 457 · cited 1×
“Myc-epitope-tagged versions of complementary DNAs containing these mutations were transiently expressed in COS cells, immunoprecipitated using the Myc-tag and examined in a kinase cascade assay using bacterially produced glutathione S -transferase (GST)–MEK, GST–ERK and myelin basic protein (MBP) as sequential substra…”
MethodSelf-citationDifferential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456 · cited 1×
“Myc-epitope-tagged versions of complementary DNAs containing these mutations were transiently expressed in COS cells, immunoprecipitated using the Myc-tag and examined in a kinase cascade assay using bacterially produced glutathione S -transferase (GST)–MEK, GST–ERK and myelin basic protein (MBP) as sequential substra…”
MethodSelf-citationRas Activation of the Raf Kinase: Tyrosine Kinase Recruitment of the MAP Kinase Cascade
Avruch, J. (2001) · Recent Progress in Hormone Research · doi:10.1210/rp.56.1.127 · Cited by 391 · cited 1×
“The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RA”
Background
Cited by
Items 501–600 of 1,150
Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma
Lin, W. M., Baker, A. C., Beroukhim, R., Winckler, W., Feng, W., Marmion, J. M., Laine, E., Greulich, H., Tseng, H., Gates, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2615 · Cited by 297
“In melanoma, the MAP kinase pathway is commonly activated by BRAF or NRAS oncogene point mutations, and BRAF(V600E) mutation is associated with sensitivity to RAF or MEK inhibition.”
BackgroundResultInfluentialBRAF mutations in papillary carcinomas of the thyroid
Fukushima, T., Suzuki, S., Mashiko, M., Ohtake, T., Endo, Y., Takebayashi, Y., Sekikawa, K., Hagiwara, K., & Takenoshita, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206739 · Cited by 297
“It has been shown that mutant BRAF proteins have elevated kinase activity and can transform NIH3T3 cells (Davies et al., 2002).”
BackgroundResultInfluentialGenomics and the Continuum of Cancer Care
McDermott, U., Downing, J. R., & Stratton, M. R. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0907178 · Cited by 299
Self-citationHouben, R., Becker, J. C., Kappel, A., Terheyden, P. A. M., Bröcker, E., Goetz, R., & Rapp, U. R. (2004) · Journal of Carcinogenesis · doi:10.1186/1477-3163-3-6 · Cited by 325
“Recently, mutations in the BRAF gene, which is localized on chromosome 7, have been reported in melanoma [6,7].”
BackgroundResultInfluentialOncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Waldman, T. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_68 · Cited by 291
“1998) or KRAS and BRAF mutations (Davies et al. 2002; Rajagopalan et al. 2002).”
BackgroundRole of mitogen-activated protein kinase kinase kinases in signal integration
Cuevas, B. D., Abell, A. N., & Johnson, G. L. (2007) · Oncogene · doi:10.1038/sj.onc.1210409 · Cited by 294
“Davies et al. (2002) found B-Raf to be mutated in >60% of malignant melanomas, and other studies have determined that it is frequently mutated in cancers of the thyroid, colon and ovary, and is mutated at a lower frequency in a variety of other cancers (Beeram et al., 2005).”
BackgroundMEK and the inhibitors: from bench to bedside
Akinleye, A., Furqan, M., Mukhi, N., Ravella, P., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-27 · Cited by 291
“A large-scale cancer genome sequencing study revealed that B-Raf is mutated in about 20% of all cancers and in more than 60% of melanomas [18].”
Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Janakiraman, M., Vakiani, E., Zeng, Z., Pratilas, C. A., Taylor, B. S., Chitale, D., Halilovic, E., Wilson, M., Huberman, K., Ricarte Filho, J. C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0192 · Cited by 290
“Clinical testing, however, has been restricted to the identification of mutations involving only few of the most commonly mutated alleles (14, 15).”
BackgroundLee, J., Lee, E., & Kim, Y. (2007) · Cancer · doi:10.1002/cncr.22754 · Cited by 291
“The most common BRAF mutation is the T1799A transversion mutation (formerly referred to as the BRAF T1796A mutation) in exon 15 of the gene, which causes a V600E (formerly termed V599E) amino acid substitution in the protein and consequent constitutive activation of the kinase.(8) In thyroid tumors, the BRAF mutation…”
BackgroundMistry, M., Zhukova, N., Merico, D., Rakopoulos, P., Krishnatry, R., Shago, M., Stavropoulos, J., Alon, N., Pole, J. D., Ray, P. N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3922 · Cited by 288
Molecularly targeted cancer therapy: some lessons from the past decade
Huang, M., Shen, A., Ding, J., & Geng, M. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.11.004 · Cited by 291
Personalized Medicine: Recent Progress in Cancer Therapy
Gambardella, V., Tarazona, N., Cejalvo, J. M., Lombardi, P., Huerta, M., Roselló, S., Fleitas, T., Roda, D., & Cervantes, A. (2020) · Cancers · doi:10.3390/cancers12041009 · Cited by 282
“BRAF mutations are major oncogenic drivers in 7% of solid tumors [60].”
BackgroundIntegrin signaling in malignant melanoma
Kuphal, S., Bauer, R., & Bosserhoff, A.-K. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-1572-1 · Cited by 289
“Ras function does not seem to be required for the growth of cancer cell lines with the B-Raf mutation [152].”
BackgroundOncogenic Ras in tumour progression and metastasis
Giehl, K. (2005) · Biological Chemistry · doi:10.1515/bc.2005.025 · Cited by 287
“…reported in several tumours and the recent discovery of activated B-raf alleles in colon cancer cells, melanoma cells, and certain other cancer cells supports the importance of this signal transduction pathway in cancer progression and/or maintenance (Davies et al., 2002; Rajagopalan et al., 2002).”
BackgroundPaez, J. G. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh069 · Cited by 290
Rahmani, M., Davis, E. M., Bauer, C., Dent, P., & Grant, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506551200 · Cited by 288
Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors
Powers, M. V., & Workman, P. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01324 · Cited by 285
Rewired ERK-JNK Signaling Pathways in Melanoma
Lopez-Bergami, P., Huang, C., Goydos, J. S., Yip, D., Bar-Eli, M., Herlyn, M., Smalley, K. S. M., Mahale, A., Eroshkin, A., Aaronson, S., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.03.009 · Cited by 286
Scientific Advances in Lung Cancer 2015
Tsao, A. S., Scagliotti, G. V., Bunn, P. A., Carbone, D. P., Warren, G. W., Bai, C., de Koning, H. J., Yousaf-Khan, A. U., McWilliams, A., Tsao, M. S., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.03.012 · Cited by 284
Ultraviolet radiation and cutaneous malignant melanoma
Jhappan, C., Noonan, F. P., & Merlino, G. (2003) · Oncogene · doi:10.1038/sj.onc.1206450 · Cited by 283
“The role of RAS/BRAF in regulating vital melanocytic activities may be significant, particularly in light of the recent discovery that 66% of cultured and primary melanoma cells harbor activating BRAF mutations (Davies et al., 2002).”
BackgroundSievert, A. J., Lang, S.-S., Boucher, K. L., Madsen, P. J., Slaunwhite, E., Choudhari, N., Kellet, M., Storm, P. B., & Resnick, A. C. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219232110 · Cited by 285
“The vast majority (>90%) of BRAF mutations represent a single amino acid substitution of valine to glutamate in exon 15 at residue 600 (V600E) (6).”
BackgroundIntra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma
Yancovitz, M., Litterman, A., Yoon, J., Ng, E., Shapiro, R. L., Berman, R. S., Pavlick, A. C., Darvishian, F., Christos, P., Mazumdar, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029336 · Cited by 283
“90% of BRAF mutations found in melanoma [8], and”
BackgroundResultMAP kinase pathways: The first twenty years
Avruch, J. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.11.006 · Cited by 281
“The more recent discovery of activating mutations in BRaf, especially in malignant melanoma [180] added further impetus to the search for clinically useful inhibitors of this pathway, and several agents directed toward Raf and MAP2Ks are now in clinical trials [181,182].”
BackgroundSerrated Polyps and Colorectal Cancer: New Pathway to Malignancy
Noffsinger, A. E. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092317 · Cited by 282
ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy?
Buscà, R., Pouysségur, J., & Lenormand, P. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00053 · Cited by 284
“For example, at the Raf level, B-Raf displays a greater specific activity than A-Raf and C-Raf, and partners of Raf kinases vary greatly (Desideri et al., 2015).”
BackgroundParmenter, T. J., Kleinschmidt, M., Kinross, K. M., Bond, S. T., Li, J., Kaadige, M. R., Rao, A., Sheppard, K. E., Hugo, W., Pupo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0440 · Cited by 283
Martin, G. S. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00216-2 · Cited by 281
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
Zhang, G., Frederick, D. T., Wu, L., Wei, Z., Krepler, C., Srinivasan, S., Chae, Y. C., Xu, X., Choi, H., Dimwamwa, E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82661 · Cited by 286
“Approximately 50% of melanoma patients’ tumors harbor a BRAFV600 mutation, resulting in constitutively activated MAPK signaling (2).”
BackgroundNakayama, M., & Oshima, M. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy075 · Cited by 282
“BRAF is one of the major driver genes of colorectal cancers, and the most frequent somatic mutation is a point mutation at codon 600 (BRAF), which results in a several hundred-fold increase in kinase activity compared with wildtype (Davies et al., 2002).”
BackgroundYang, S., Farraye, F. A., Mack, C., Posnik, O., & O’Brien, M. J. (2004) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000141404.56839.6a · Cited by 286
“Primers for BRAF exon 11 sequencing were those published by Davies et al.(3) HPs were initially screened for BRAF exon 15, codon 599 point mutations by AS-PCR, and the mutations identified were confirmed by direct sequencing (Fig.”
BackgroundMethodInfluentialTherapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair.
Wang, L., Cunningham, J. M., Winters, J. L., Guenther, J. C., French, A. J., Boardman, L. A., Burgart, L. J., McDonnell, S. K., Schaid, D. J., & Thibodeau, S. N. (2003) · PubMed · Cited by 282
Sinicrope, F. A., Mahoney, M. R., Smyrk, T. C., Thibodeau, S. N., Warren, R. S., Bertagnolli, M. M., Nelson, G. D., Goldberg, R. M., Sargent, D. J., & Alberts, S. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.9591 · Cited by 279
“The BRAF oncogene encodes a serine/ threonine kinase and is a downstream effector of the Ras/Raf/MAPK signaling pathway.(8,9) BRAF or KRAS mutations predict nonresponse to anti–epidermal growth factor receptor antibody therapy in metastatic CRCs, although only KRAS has been validated.”
BackgroundTargeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
Hughes, P. E., Caenepeel, S., & Wu, L. C. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.010 · Cited by 282
“Combinations of MAPK Pathway Inhibitors with Checkpoint Therapies The serine threonine kinase BRAF is mutated in approximately half of all malignant melanomas [31].”
BackgroundMissense mutations of the BRAF gene in human lung adenocarcinoma.
Naoki, K., Chen, T. H., Richards, W. G., Sugarbaker, D. J., & Meyerson, M. M. (2002) · PubMed · Cited by 287
Colorectal liver metastases: Current management and future perspectives
Martin, J., Petrillo, A., Smyth, E. C., Shaida, N., Khwaja, S., Cheow, H., Duckworth, A., Heister, P., Praseedom, R., Jah, A., et al. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i10.761 · Cited by 275
Kakadia, S., Yarlagadda, N., Awad, R., Kundranda, M., Niu, J., Naraev, B., Mina, L., Dragovich, T., Gimbel, M., & Mahmoud, F. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s182721 · Cited by 277
“Introduction Nearly half of patients with metastatic melanomas harbor a valine–glutamine substitution in codon 600 of the serine/threonine kinase BRAF (BRAF mutation).(1) These melanomas have all the features of oncogene addiction to the BRAF-mutated gene (Figure 1).”
New insight into BRAF mutations in cancer
Dhomen, N., & Marais, R. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.005 · Cited by 278
“Lessons from melanoma Importantly, up to 70% of human melanomas, a form of skin cancer that arises from the melanocyte lineage, harbour mutations in BRAF [7].”
BackgroundInfluentialSelf-citationDiagnosis and Molecular Classification of Lung Cancer
Rodriguez-Canales, J., Parra-Cuentas, E., & Wistuba, I. I. (2016) · Cancer Treatment and Research · doi:10.1007/978-3-319-40389-2_2 · Cited by 273
“Mutations in BRAF are more commonly seen in melanoma (50–70 %) than in lung cancer, where they have been found in 1–4 % [97–103].”
BackgroundFlockhart, R. J., Webster, D. E., Qu, K., Mascarenhas, N., Kovalski, J., Kretz, M., & Khavari, P. A. (2012) · Genome Research · doi:10.1101/gr.140061.112 · Cited by 277
“Activating mutations in the BRAF oncogene are present in >70% of melanomas, ;90% of which are BRAFV600E (Davies et al. 2002; Rubinstein et al. 2010).”
Melanoma epidemiology, biology and prognosis
Ali, Z., Yousaf, N., & Larkin, J. (2013) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2013.07.012 · Cited by 278
“Mutations affecting this pathway are present in the vast majority of cutaneous melanomas, predominantly affecting the NRAS (approximately 20%) [69] or BRAF (approximately 40–50%) proteins [70].”
BackgroundCancer Cells Tune the Signaling Pathways to Empower de Novo Synthesis of Nucleotides
Villa, E., Ali, E., Sahu, U., & Ben-Sahra, I. (2019) · Cancers · doi:10.3390/cancers11050688 · Cited by 281
“K-RAS mutations are frequent in different types of cancer [76], being found in approximately 15% of human cancers [77].”
BackgroundThe Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications
Delire, B., & Stärkel, P. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12441 · Cited by 275
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Brand, T. M., Iida, M., & Wheeler, D. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15050 · Cited by 273
BRAF targeted therapy changes the treatment paradigm in melanoma
Ribas, A., & Flaherty, K. T. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.69 · Cited by 271
“This led to the description of the BRAF V600E mutation in 2002”
BackgroundWyman, K., Atkins, M. B., Prieto, V., Eton, O., McDermott, D. F., Hubbard, F., Byrnes, C., Sanders, K., & Sosman, J. A. (2006) · Cancer · doi:10.1002/cncr.21834 · Cited by 274
Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF
Wellbrock, C., Rana, S., Paterson, H., Pickersgill, H., Brummelkamp, T., & Marais, R. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002734 · Cited by 278
“position 600 (V600E) [3].”
Self-citationOncogenic Ras and its role in tumor cell invasion and metastasis
Campbell, P. M., & Der, C. J. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.09.015 · Cited by 275
“[41] Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S,”
BackgroundLelièvre, P., Sancey, L., Coll, J.-L., Deniaud, A., & Busser, B. (2020) · Cancers · doi:10.3390/cancers12123594 · Cited by 271
“The targeting of Cu with TTM induced antitumor effects in cells with BRAF V600E kinase mutations, which gave a strong rationale for the further development of several secondary studies aiming at disrupting the central role of Cu in other BRAF V600E-positive malignancies, such as thyroid, lung, and colorectal cancers o…”
BackgroundBRAFE600 in benign and malignant human tumours
Michaloglou, C., Vredeveld, L. C. W., Mooi, W. J., & Peeper, D. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210704 · Cited by 275
“Although a large proportion of common acquired naevi harbour mutant BRAF, hardly any such mutations have been identified in Spitz naevi, which typically harbour HRAS mutations and/or amplification (see below; Bastian et al., 2000).”
BackgroundInfluentialYu, C., Bruzek, L. M., Meng, X. W., Gores, G. J., Carter, C. A., Kaufmann, S. H., & Adjei, A. A. (2005) · Oncogene · doi:10.1038/sj.onc.1208841 · Cited by 277
“…of B-Raf have been reported in approximately 70% of malignant melanomas and in a smaller fraction of other cancer types (ovarian, thyroid, colon, lung) (Davies et al., 2002; Pollock and Meltzer, 2002; Cohen et al., 2003; Mercer and Pritchard, 2003; Singer et al., 2003; Tannapfel et al., 2003).”
BackgroundWhiteman, D. C., Pavan, W. J., & Bastian, B. C. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00880.x · Cited by 273
“BRAF and melanoma Contrasting with the findings for NRAS, BRAF mutations, originally discovered in melanoma cell lines (Davies et al., 2002), have been reproducibly associated with specific clinical and histopathological characteristics Whiteman et al.”
BackgroundResultLiu, Z.-J., Xiao, M., Balint, K., Smalley, K. S. M., Brafford, P., Qiu, R., Pinnix, C. C., Li, X., & Herlyn, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3589 · Cited by 271
“Thus far, aberrations of several cellular signaling pathways, such as B-Raf (2), N-Ras (3), p16INK4 (4), p53/ Apaf-1 (5), PTEN/Akt (6), cyclin D1/cyclin-dependent kinase 4 (7, 8), Wnt5a (9), and Grm-1 (10), have been suggested in melanocyte transformation and melanoma progression.”
BackgroundMitogen-actived protein kinase activation is an early event in melanoma progression.
Cohen, C., Zavala-Pompa, Á., Sequeira, J., Shoji, M., Sexton, D. G., Cotsonis, G., Cerimele, F., Govindarajan, B., Macaron, N. C., & Arbiser, J. L. (2002) · PubMed · Cited by 275
Therapeutic cancer vaccines: Are we there yet?
Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00979.x · Cited by 271
“patients harboring this mutation (19) have very high objective”
BackgroundCodon-specific translation reprogramming promotes resistance to targeted therapy
Rapino, F., Delaunay, S., Rambow, F., Zhou, Z., Tharun, L., De Tullio, P., Sin, O., Shostak, K., Schmitz, S., Piepers, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0243-7 · Cited by 271
Retroviral insertional mutagenesis: past, present and future
Uren, A. G., Kool, J., Berns, A., & van Lohuizen, M. (2005) · Oncogene · doi:10.1038/sj.onc.1209043 · Cited by 271
“These insertions create a truncated transcript, which while not equivalent to BRAF mutations seen in human melanoma (Davies et al., 2002), is nonetheless capable of inducing foci formation in NIH 3T3 cells.”
BackgroundRegulation of Hippo Signaling by EGFR-MAPK Signaling through Ajuba Family Proteins
Reddy, B. V. V. G., & Irvine, K. D. (2013) · Developmental Cell · doi:10.1016/j.devcel.2013.01.020 · Cited by 271
“Raf-V600E is an active form of BRAF with somatic mutation in kinase domain (V600E), observed in human cancers (Davies et al., 2002).”
BackgroundGrob, J. J., Amonkar, M. M., Karaszewska, B., Schachter, J., Dummer, R., Mackiewicz, A., Stroyakovskiy, D., Drucis, K., Grange, F., Chiarion-Sileni, V., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00087-x · Cited by 269
Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas
Fransen, K. (2003) · Carcinogenesis · doi:10.1093/carcin/bgh049 · Cited by 268
“In agreement with earlier studies ( 8 ,9), statistical analysis showed that mutations in the KRAS and BRAF genes were mutually exclusive and in no case in the present study could such mutations be observed simultaneously.”
BackgroundResultInfluentialA novel AKT3 mutation in melanoma tumours and cell lines
Davies, M. A., Stemke-Hale, K., Tellez, C., Calderone, T. L., Deng, W., Prieto, V. G., Lazar, A. J. F., Gershenwald, J. E., & Mills, G. B. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604637 · Cited by 272
Wnt Signaling in Skin Development, Homeostasis, and Disease
Lim, X., & Nusse, R. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008029 · Cited by 268
“The suppression of Wnt/b-catenin signaling may be achieved through the BRAF oncogene, which is constitutively activated by the BRAFV600E mutation in the majority of melanomas (Davies et al. 2002; Biechele et al. 2012).”
BackgroundThe Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer
Hilger, R. A., Scheulen, M. E., & Strumberg, D. (2002) · Oncology Research and Treatment · doi:10.1159/000068621 · Cited by 265
The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Sheppard, K. E., & McArthur, G. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0259 · Cited by 265
“Similar to melanoma (60), benign nevi harbor activating mutations in BRAF (61) and, less frequently, NRAS (62).”
BackgroundRiesco-Eizaguirre, G., Rodríguez, I., De la Vieja, A., Costamagna, E., Carrasco, N., Nistal, M., & Santisteban, P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1248 · Cited by 265
Meier, F. (2005) · Frontiers in Bioscience · doi:10.2741/1755 · Cited by 267
“A recent discovery has excited the melanoma research community (9).”
BackgroundPrognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges
Koncina, E., Haan, S., Rauh, S., & Letellier, E. (2020) · Cancers · doi:10.3390/cancers12020319 · Cited by 259
“The BRAF gene is activated by mutations in 10% of CRC [66].”
BackgroundTrovisco, V., Soares, P., Preto, A., de Castro, I. V., Lima, J., Castro, P., Máximo, V., Botelho, T., Moreira, S., Meireles, A. M., et al. (2005) · Virchows Archiv · doi:10.1007/s00428-005-1236-0 · Cited by 253
“Mutations from valine to glutamic acid at the residue 600 (formerly referred as residue 599 [10]) of the BRAF gene, first described with a high frequency in melanoma [3, 7], were found to be highly prevalent in PTC in several series [6, 9, 13, 22, 26].”
Frattini, M., Ferrario, C., Bressan, P., Balestra, D., De Cecco, L., Mondellini, P., Bongarzone, I., Collini, P., Gariboldi, M., Pilotti, S., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207980 · Cited by 266
“The V599E mutation leads to an increase of BRAF basal kinase activity, resulting in a constitutive activation of the BRAF/MAP kinases pathway (Davies et al., 2002).”
BackgroundMethodInfluentialNatural products: An upcoming therapeutic approach to cancer
Dutta, S., Mahalanobish, S., Saha, S., Ghosh, S., & Sil, P. C. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.04.012 · Cited by 259
The cancer genome atlas pan-cancer analysis project
Mills, G. B., Mills Shaw, K. R., Shmulevich, I., Stuart, J. M., Ellrott, K., Sander, C., The Cancer Genome Atlas Research Network, Collisson, E. A., Ozenberger, B. A., & Weinstein, J. N. (2019) · PubMed · doi:10.17615/670y-yr53 · Cited by 261
MEK in cancer and cancer therapy
Neuzillet, C., Tijeras-Raballand, A., de Mestier, L., Cros, J., Faivre, S., & Raymond, E. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.001 · Cited by 264
Kumar, V., Vashishta, M., Kong, L., Wu, X., Lu, J. J., Guha, C., & Dwarakanath, B. S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.650772 · Cited by 255
Platz, A., Egyhazi, S., Ringborg, U., & Hansson, J. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2007.12.003 · Cited by 260
“The V600E alteration may mimic the T599/S602 phosphorylation since it was shown that the V600E mutant B-raf has a higher kinase activity than wild type B-raf (Davies et al., 2002).”
BackgroundInfluentialSchmid, K., Oehl, N., Wrba, F., Pirker, R., Pirker, C., & Filipits, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0089 · Cited by 262
Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., Testori, A., Lorigan, P. C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx339 · Cited by 262
Cellular senescence in vivo: a barrier to tumorigenesis
Prieur, A., & Peeper, D. S. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.01.007 · Cited by 260
The INK4a/ARF locus and melanoma
Sharpless, N. E., & Chin, L. (2003) · Oncogene · doi:10.1038/sj.onc.1206461 · Cited by 261
“On the genetic level, the signature events in melanoma include activation of the Ras/Raf pathway (Davies et al., 2002; Herlyn and Satyamoorthy, 1996) and loss of INK4a/ARF locus function (Flores et al., 1996; Walker et al., 1998).”
BackgroundRegulation of TEAD Transcription Factors in Cancer Biology
Huh, H., Kim, D., Jeong, H.-S., & Park, H. (2019) · Cells · doi:10.3390/cells8060600 · Cited by 259
“Approximately half of metastatic melanoma patients harbor the BRAFV600 mutation, with the most common being BRAFV600E [172].”
BackgroundShimamura, T., Lowell, A. M., Engelman, J. A., & Shapiro, G. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0933 · Cited by 259
“Conversely, BRAF mutation, present with highest frequency in malignant melanoma compared with other cancer cell types (51),”
BackgroundProtein kinase inhibitors: contributions from structure to clinical compounds
Johnson, L. N. (2009) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583508004745 · Cited by 256
“Second in the list was B-RAF, a protein kinase that had been identified from a previous screen as an oncogene (Davies et al. 2002a).”
BackgroundAbrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis
Vredeveld, L. C. W., Possik, P. A., Smit, M. A., Meissl, K., Michaloglou, C., Horlings, H. M., Ajouaou, A., Kortman, P. C., Dankort, D., McMahon, M., et al. (2012) · Genes & Development · doi:10.1101/gad.187252.112 · Cited by 262
“The primary molecular engine driving melanomagenesis is the activation of the ERK pathway, mainly due to oncogenic mutation of BRAF (Davies et al. 2002; Pollock et al. 2003) or NRAS (Raybaud et al. 1988; van’t Veer et al. 1989).”
BackgroundInfluentialOncogene-induced senescence: the bright and dark side of the response
Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.07.013 · Cited by 257
“The prototypic oncogenes linked with senescence in vivo were the mutant RAS family members, K-RAS [12 ,13], frequently mutated in lung and pancreatic adenocarcinomas [14], N-RAS [15 ], and the mutant downstream effector of RAS, BRAF [16 ,17,18], first observed in melanocytic nevi and further found in colon and nonsmal…”
BackgroundA conditional feedback loop regulates Ras activity through EphA2
Macrae, M., Neve, R. M., Rodriguez-Viciana, P., Haqq, C., Yeh, J., Chen, C., Gray, J. W., & McCormick, F. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.07.005 · Cited by 260
“This may account for high levels of EphA2 in many cancer cells, such as in malignant melanoma, in which the RasRaf-MAPK pathway is invariably activated, through activation of either Ras or B-Raf (Davies et al., 2002).”
BackgroundSalvatore, G., Giannini, R., Faviana, P., Caleo, A., Migliaccio, I., Fagin, J. A., Nikiforov, Y. E., Troncone, G., Palombini, L., Basolo, F., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032221 · Cited by 259
“upstream of MAPK kinase in the classic MAPK cascade (18).”
BackgroundBRAFV599EMutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas
Puxeddu, E., Moretti, S., Elisei, R., Romei, C., Pascucci, R., Martinelli, M., Marino, C., Avenia, N., Rossi, E. D., Fadda, G., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031425 · Cited by 260
Rheault, T. R., Stellwagen, J. C., Adjabeng, G. M., Hornberger, K. R., Petrov, K. G., Waterson, A. G., Dickerson, S. H., Mook, R. A., Laquerre, S. G., King, A. J., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000063 · Cited by 253
Resistant mechanisms to BRAF inhibitors in melanoma
Manzano, J. L., Layos, L., Bugés, C., de los Llanos Gil, M., Vila, L., Martínez-Balibrea, E., & Martínez-Cardús, A. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.06.07 · Cited by 255
“The discovery of hotspot mutations in BRAF V600E, a key serine-threonine kinase in the RAS-RAF-MEK-ERK (MAPK pathway) signaling pathway, led to development of molecular targeted therapies for melanoma (2).”
BackgroundITO, Y., YOSHIDA, H., MARUO, R., MORITA, S., TAKANO, T., HIROKAWA, M., YABUTA, T., FUKUSHIMA, M., INOUE, H., TOMODA, C., et al. (2009) · Endocrine Journal · doi:10.1507/endocrj.k08e-208 · Cited by 255
Synthesis and biological activity of vicinal diaryl-substituted 1H-imidazoles
Bellina, F., Cauteruccio, S., & Rossi, R. (2007) · Tetrahedron · doi:10.1016/j.tet.2007.02.075 · Cited by 254
Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants
Hocker, T., & Tsao, H. (2007) · Human Mutation · doi:10.1002/humu.20481 · Cited by 257
Systemic treatments for metastatic cutaneous melanoma
Pasquali, S., Hadjinicolaou, A. V., Chiarion Sileni, V., Rossi, C. R., & Mocellin, S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011123.pub2 · Cited by 237
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
Qing, J., Du, X., Chen, Y., Chan, P., Li, H., Wu, P., Marsters, S., Stawicki, S., Tien, J., Totpal, K., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38017 · Cited by 255
Sievert, A. J., Jackson, E. M., Gai, X., Hakonarson, H., Judkins, A. R., Resnick, A. C., Sutton, L. N., Storm, P. B., Shaikh, T. H., & Biegel, J. A. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00225.x · Cited by 255
“Primers for exons 11 and 15 of the BRAF gene have been described (5).”
BackgroundToward a Molecular Classification of Melanoma
Fecher, L. A., Cummings, S. D., Keefe, M. J., & Alani, R. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0442 · Cited by 252
BRAF Inhibition in Refractory Hairy-Cell Leukemia
Dietrich, S., Glimm, H., Andrulis, M., von Kalle, C., Ho, A. D., & Zenz, T. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1202124 · Cited by 255
Genetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer
Pratilas, C. A., Hanrahan, A. J., Halilovic, E., Persaud, Y., Soh, J., Chitale, D., Shigematsu, H., Yamamoto, H., Sawai, A., Janakiraman, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2223 · Cited by 255
“9% of the total cases analyzed, an incidence consistent with previous reports (13, 14, 21).”
BackgroundResultPrognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer
French, A. J., Sargent, D. J., Burgart, L. J., Foster, N. R., Kabat, B. F., Goldberg, R., Shepherd, L., Windschitl, H. E., & Thibodeau, S. N. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1489 · Cited by 251
“reported the presence of BRAF somatic mutations in 66% of malignant melanomas and at a lower frequency in a wide range of other human cancers, including colon cancers (22).”
BackgroundElser, C., Siu, L. L., Winquist, E., Agulnik, M., Pond, G. R., Chin, S. F., Francis, P., Cheiken, R., Elting, J., McNabola, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2871 · Cited by 252
Noonan Syndrome: Clinical Aspects and Molecular Pathogenesis
Tartaglia, M., Zampino, G., & Gelb, B. D. (2010) · Molecular Syndromology · doi:10.1159/000276766 · Cited by 246
“Due to its nodal role in signal transduction, signal traffic through this pathway is tightly controlled, and its enhanced activation has been established to contribute significantly to oncogenesis (see below) [Bos, 1989; Davies et al., 2002; Rajalingam et al., 2007].”
Background
Metadata
- Authors
- Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W. C., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., & Futreal, P. A.
- Affiliations
- Wellcome Sanger Institute (GB)
- Institute of Cancer Research (GB)
- Western Infirmary (GB)
- University of York (GB)
- Duke University (US)
- National Research Council (IT)
- University of Sassari (IT)
- Royal Brompton Hospital (GB)
- Queen Mary Hospital (CN)
- Abramson Cancer Center (US)
- Corresponding author
- Wooster, Richard
- ORCID
- Davies, Helen
- Edkins, Sarah
- Teague, Jon
- Garnett, Mathew J.
- Dicks, Ed
- Gray, Kristian
- Hughes, Jaime
- Kosmidou, Vivian
- Menzies, Andrew
- Watt, Stephen
- Hooper, Steven
- Shipley, Janet
- Hargrave, Darren
- Maitland, Norman
- Riggins, Gregory J.
- Bigner, Darell D.
- Palmieri, Giuseppe
- Cossu, Antonio
- Flanagan, Adrienne
- Nicholson, Andrew
- Ho, Judy W. C.
- Yuen, Siu T.
- Paterson, Hugh
- Marais, Richard
- Stratton, Michael R.
- Futreal, P. Andrew
- Venue
- Nature
- Published
- 2002-06
- Volume
- 417
- Issue
- 6892
- Pages
- 949-954
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2163188200
- Cited by
- 10,674
- References
- 24
- Citations by year
- 2026: 221 · 2025: 282 · 2024: 435 · 2023: 450 · 2022: 442 · 2021: 506 · 2020: 538 · 2019: 482 · 2018: 519 · 2017: 576 · 2016: 576 · 2015: 649 · 2014: 701 · 2013: 688 · 2012: 563
- FWCI
- 87.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- BRAF mutation, somatic missense mutations, melanoma, oncogenic Ras, kinase activity, malignant transformation, therapeutic target
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Cell Division, Cell Transformation, Neoplastic, DNA Mutational Analysis, Enzyme Activation, Humans, Melanoma, Molecular Sequence Data, Neoplasms, Tumor Cells, Cultured, 3T3 Cells, Protein Structure, Tertiary, ras Proteins, Proto-Oncogene Proteins c-raf, Mutation, Missense, Mitogen-Activated Protein Kinases, MAP Kinase Signaling System, Proto-Oncogene Proteins B-raf, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.